FCER2 and atherosclerosis: Finally, as proof of concept that B2 cells can be targeted therapeutically to reduce atherosclerosis, we demonstrated that an anti-B2-cell antibody (CD23) effectively prevented commensal microbe-derived atherosclerosis in response to hyperlipidemia.